Electronic database Medline, Embase, Cochrane Library and Lilacs were used to retrieve the clinical trials that will evaluate the various therapeutical options available for management of hemorrhagic dengue. Eight clinical studies were included. Supportive care and symptomatic treatment through hydration and aggressive fluid management, if hypotension develops in the course of disease, are the most important aids to improve survival. Treatment with corticosteroids such as methylprednisolone, hydrocortisone, carbazochorome sodium sulfonate (AC-17) and recombinant activated factor VII did not reduce mortality in children with hemorrhagic dengue. At present, no vaccine or effective antiviral treatment is available for the prevention or treatment of hemorrhagic dengue.
